On June 22, AbbVie announced an agreement to acquire immunology-focused biopharma firm Apogee Therapeutics for $10.1 billion (net of cash acquired). The deal is expected to close in the third quarter. AbbVie shares rose 6%.
AbbVie's next-generation immunology drugs targeting the IL-23 (Skyrizi) and JAK (Rinvoq) pathways are mitigating biosimilar headwinds to older blockbuster Humira.
AbbVie has had to depend on acquisitions to boost its late-stage pipeline, suggesting less successful internal research and development activities.
|
Metric
|
ABBV
|
JNJ
|
LLY
|
|---|---|---|---|
Price/Earnings (Normalized) | 24.97 | 23.38 | 40.08 |
Price/Book Value | — | 7.50 | 33.77 |
Price/Sales | 7.18 | 6.30 | 14.66 |
Price/Cash Flow | 19.69 | 20.68 | 39.41 |
|
Metric
|
ABBV
|
JNJ
|
LLY
|
|---|---|---|---|
Quick Ratio | 0.52 | 0.77 | 0.72 |
Current Ratio | 0.80 | 1.03 | 1.50 |
Interest Coverage | 2.96 | 24.09 | — |
|
Metric
|
ABBV
|
JNJ
|
LLY
|
|---|---|---|---|
Return on Assets (Normalized) | 13.37% | — | 24.73% |
Return on Equity (Normalized) | — | — | 114.33% |
Return on Invested Capital (Normalized) | 29.17% | — | 40.96% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|k&@@f!^ | LOCK|!jd | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|LcKP$V@ | LOCK|F?> | $609B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|gg&THV^m | LOCK|&@@ | $330B | |||
| Merck & Co Inc
MRK
| LOCK|BJ<>#! | LOCK|!GN | $315B | |||
| Novartis AG ADR
NVS
| LOCK|ww<<MwW | LOCK|syS | $295B | |||
| AstraZeneca PLC
AZN
| LOCK|yvHj%<b | LOCK|K@ | $263B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|K!g#BR | LOCK|TK | $223B | |||
| Amgen Inc
AMGN
| LOCK|G!zC#<bS | LOCK|<$ | $198B | |||
| Gilead Sciences Inc
GILD
| LOCK|G#Mg^vM | LOCK|k#x | $167B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
United States